New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:47 EDTZIOP, EBS, JNJ, UHS, AUXL, HCA, PFE, WAG, CAH, HLS, TSROMizuho to hold a conference
USA Healthcare Corporate Access Day is being held in New York on May 6.
News For WAG;UHS;TSRO;PFE;JNJ;HLS;HCA;EBS;CAH;AUXL;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 22, 2015
16:32 EDTHLSHealthSouth, CHI St. Vincent Hot Springs announce inpatient rehabilitation JV
Subscribe for More Information
10:00 EDTZIOPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
08:52 EDTPFEPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:59 EDTZIOPZiopharm downgraded on valuation, competition at BMO Capital
As noted earlier, BMO Capital downgraded Ziopharm Market Perform from Outperform. As reasons for the downgrade, the firm cited valuation, increased competition, and its belief that the company has fallen further behind its competitors. Target to $10 from $15.
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
06:37 EDTHCA, UHSHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
06:29 EDTZIOPZiopharm downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
June 21, 2015
13:51 EDTHCAShares of HCA Holdings could see 20% upside in two years, Barron's says
Subscribe for More Information
June 19, 2015
10:09 EDTUHS, HCAFly Watch: Supreme Court may release key ACA decision soon
Subscribe for More Information
08:30 EDTZIOPZiopharm data positive, says BMO Capital
Subscribe for More Information
07:37 EDTUHS, HCASupreme Court decision on ACA suit due soon, says UBS
Subscribe for More Information
05:40 EDTTSROTESARO a favorite stock for second half of year at Mizuho
Subscribe for More Information
June 18, 2015
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
07:38 EDTUHS, HCALeerink to hold a roundtable
Subscribe for More Information
June 17, 2015
10:00 EDTPFEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
07:47 EDTHLSHealthSouth and Mount Carmel Health to build rehabilitation hospital in Ohio
HealthSouth and Mount Carmel Health System have signed an agreement to begin construction on a new inpatient rehabilitation hospital in Westerville, Ohio. The 60-bed hospital will be a joint venture between HealthSouth and Mount Carmel and will provide specialized rehabilitative care to patients who have experienced stroke, trauma, brain and orthopedic injuries or other major illnesses or injuries. Construction on the 60,000-square-foot hospital is expected to begin in Q4 and to be completed by 1Q17.
07:25 EDTPFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use